U.S. Markets close in 4 hrs 3 mins

Agios Pharmaceuticals, Inc. (AGIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
54.90-0.29 (-0.53%)
As of 11:56AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close55.19
Open55.61
Bid55.06 x 1200
Ask55.13 x 900
Day's Range54.73 - 55.87
52 Week Range32.47 - 58.93
Volume176,395
Avg. Volume779,446
Market Cap3.827B
Beta (5Y Monthly)1.64
PE Ratio (TTM)N/A
EPS (TTM)-4.74
Earnings DateApr 29, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est63.00
  • Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for

    Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Is AGIO Stock A Buy or Sell?
    Insider Monkey

    Is AGIO Stock A Buy or Sell?

    With the fourth-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the first quarter of 2021. One of these stocks was Agios Pharmaceuticals Inc (NASDAQ:AGIO). Is AGIO stock a […]

  • Agios to Webcast Conference Call of First Quarter 2021 Financial Results on April 29, 2021
    GlobeNewswire

    Agios to Webcast Conference Call of First Quarter 2021 Financial Results on April 29, 2021

    CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that the company will host a conference call and live webcast on Thursday, April 29, 2021 at 8:00 a.m. ET to report its first quarter 2021 financial results and other business highlights. A live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and referring to conference ID 4497151. The webcast will be archived and made available for replay on the company's website beginning approximately two hours after the event. About AgiosAgios is focused on discovering and developing novel investigational medicines to treat genetically defined diseases through scientific leadership in the field of cellular metabolism. The company’s most advanced drug candidate is a first-in-class pyruvate kinase R (PKR) activator, mitapivat, that is currently being evaluated for the treatment of three distinct hemolytic anemias. In addition to its active late-stage clinical pipeline, Agios has multiple novel, investigational therapies in clinical and preclinical development. For more information, please visit the company’s website at www.agios.com. ContactHolly Manning, 617-844-6630Senior Director, Investor RelationsHolly.Manning@agios.com